{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=26&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 10847, "total_pages": 1085, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=27&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=25&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T06:09:33.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00877006", "title": "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "bendamustine", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2009-04-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 79, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877006" }, { "nct_id": "NCT00080106", "title": "Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "MRK Ad5 HIV-1 gag vaccine", "type": "BIOLOGICAL" }, { "name": "Vaccine placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 114, "start_date": "2004-06", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 27, "location_summary": "Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080106" }, { "nct_id": "NCT03078478", "title": "A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin degludec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1609, "start_date": "2017-03-13", "completion_date": "2019-03-04", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 156, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078478" }, { "nct_id": "NCT04521478", "title": "A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "BI 1358894", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 389, "start_date": "2020-11-20", "completion_date": "2024-02-02", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Garden Grove", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521478" }, { "nct_id": "NCT00313300", "title": "Safety Study of Apixaban in Recent Acute Coronary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Coronary Syndrome (ACS)" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 1741, "start_date": "2006-05", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2015-12-30", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313300" }, { "nct_id": "NCT01500434", "title": "The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "PROMUS Element Coronary Stent System", "type": "DEVICE" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Thienopyridine", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2009-02", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 21, "location_summary": "La Jolla, California • Sacramento, California • San Diego, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500434" }, { "nct_id": "NCT01082549", "title": "Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Lung Cancer" ], "interventions": [ { "name": "gemcitabine/carboplatin", "type": "DRUG" }, { "name": "gemcitabine/carboplatin plus Iniparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2010-03", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082549" }, { "nct_id": "NCT06980649", "title": "Study of BHV-1300 in Graves' Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graves Disease" ], "interventions": [ { "name": "BHV-1300", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 15, "start_date": "2025-08-21", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 10, "location_summary": "South Gate, California • Miami, Florida • Columbus, Georgia + 6 more", "locations": [ { "city": "South Gate", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Greenville", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06980649" }, { "nct_id": "NCT04179409", "title": "A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "Amondys 45", "type": "DRUG" }, { "name": "Exondys 51", "type": "DRUG" }, { "name": "Vyondys 53", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kevin Flanigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "MALE", "summary": "6 Months and older · Male only" }, "enrollment_count": 3, "start_date": "2020-02-18", "completion_date": "2023-09-01", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04179409" }, { "nct_id": "NCT02569398", "title": "An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Asymptomatic Amyloid-positive" ], "interventions": [ { "name": "Atabecestat, 5 mg", "type": "DRUG" }, { "name": "Atabecestat, 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "60 Years to 85 Years" }, "enrollment_count": 557, "start_date": "2015-10-29", "completion_date": "2018-12-20", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-11-03T06:09:33.162Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02569398" } ] }